When did Lexaria Bioscience report Q1 2026 earnings?

Lexaria Bioscience (LEXX) reported Q1 2026 earnings on April 13, 2026 before market open.

What were Lexaria Bioscience's Q1 2026 revenue and EPS?

Lexaria Bioscience reported revenue of $20.0K and diluted EPS of $-0.06 for Q1 2026.

Revenue missed the consensus estimate of $50.0K by $30.0K. EPS beat the consensus estimate of $-0.10 by $0.04.

Compared to the same quarter a year prior, revenue declined 88.5% from $174.0K a year earlier and diluted EPS grew 60.0% from $-0.15.

You can read the 10-Q periodic report (0001640334-26-000687) directly on SEC EDGAR. The filing index links above go to sec.gov.

Reported April 13, 2026 · Before market open

Revenue estimate$50.0K

EPS estimate-$0.10

Jul 13, 2026 (In 3 weeks)

Revenue estimate$50.0K

EPS estimate-$0.06

Q1 2026$20.0KMiss by $30.0K

Q1 2026-$0.06Beat by $0.04

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

When did Lexaria Bioscience report Q1 2026 earnings?: Lexaria Bioscience (LEXX) reported Q1 2026 earnings on April 13, 2026 before market open.
What were Lexaria Bioscience's Q1 2026 revenue and EPS?: Lexaria Bioscience reported revenue of $20.0K and diluted EPS of $-0.06 for Q1 2026.
Did Lexaria Bioscience beat estimates in Q1 2026?: Revenue missed the consensus estimate of $50.0K by $30.0K. EPS beat the consensus estimate of $-0.10 by $0.04.
How did Lexaria Bioscience's Q1 2026 results compare year-over-year?: Compared to the same quarter a year prior, revenue declined 88.5% from $174.0K a year earlier and diluted EPS grew 60.0% from $-0.15.
Where can I find Lexaria Bioscience's Q1 2026 SEC filings?: You can read the 10-Q periodic report (0001640334-26-000687) directly on SEC EDGAR. The filing index links above go to sec.gov.